Krishna Institute of Medical Sciences Limited
All news and filings related to Krishna Institute of Medical Sciences Limited.
View all news & filings- Low impact
KIMS Hospitals to Host Analyst Call on May 18th Post Q4FY26 Results
KIMS Hospitals will hold a conference call on May 18, 2026, at 9:30 am IST. Management will discuss business strategy and outlook after Q4FY26 results. Dr. Bhaskara Rao Bollineni, Dr. Abhinay Bollineni, and Mr. Sachin Salvi will participate.
Read the summary - Medium impact
KIMS enters 60-year lease for 2-acre land in Amaravati for new 500-bed multi-speciality hospital
KIMS has signed a 60-year lease for 2 acres of land in Amaravati, Andhra Pradesh. This land will be used to develop a new 500-bed state-of-the-art multi-speciality hospital, enhancing healthcare services in the region.
Read the summary - Medium impact
KIMS Signs Strategic Clinical Collaboration MoU with Renova for Oncology Services
Krishna Institute of Medical Sciences Limited (KIMS) has signed a non-commercial brand association agreement with Renova, a specialized oncology organization. This collaboration aims to enhance KIMS's oncology services through shared clinical expertise and best practices, strengthening patient care outcomes and the company's reputation.
Read the summary - Medium impact
KIMS Shareholders Approve Qualified Institutions Placement via Postal Ballot
Krishna Institute of Medical Sciences Limited shareholders approved a special resolution for issuing equity shares via a qualified institutions placement through postal ballot. The resolution, crucial for fundraising, was passed with overwhelming majority, with e-voting concluding on April 15, 2026.
Read the summary - Low impact
KIMS: SEBI Compliance Certificate for Q4 FY26 Issued by RTA
Krishna Institute of Medical Sciences Limited (KIMS) submitted a SEBI compliance certificate for the quarter ended March 31, 2026. The certificate from the RTA confirms processing of dematerialized securities and updates to the register of members.
Read the summary - Medium impact
KIMS Subsidiary Enters 20-Year O&M, Sub-Lease Agreement with Avitis Hospitals
KIMS's subsidiary, KIMS Swastha, signed a 20-year O&M and sub-lease agreement with Avitis Super Speciality Hospitals in Palakkad, Kerala, effective April 2, 2026. KIMS will manage the 210-bedded facility. The deal involves a ₹29.75 crore security deposit for O&M and a ₹25 lakh deposit for the sub-lease. KIMS also has a call option to acquire a majority stake in Avitis.
Read the summary - Low impact
KIMS Subsidiary Receives Favorable Income Tax Order, Demand Set Aside
KIMS subsidiary SPANV Medisearch received a favorable order from the Income Tax Department on March 29, 2026. The demand notice for assessment year 2022-2023 has been set aside, resulting in zero payable amount. No financial impact is anticipated.
Read the summary - Low impact
KIMS: Trading Window Closed from April 1, 2026, for Q4 & FY26 Audited Financial Results
Krishna Institute of Medical Sciences Limited (KIMS) will close its trading window from April 1, 2026. This is for the consideration of audited financial results for the quarter and year ending March 31, 2026. The window will reopen 48 hours after the results are declared.
Read the summary - Low impact
KIMS Hospitals Announces Newspaper Publication for Postal Ballot Notice
KIMS Hospitals published a postal ballot notice on March 17, 2026, proposing a dividend of ₹0.25 per share for FY2026-27. The company plans significant investments totaling ₹500 crore to ₹1,500 crore in existing facilities and ₹500 crore to ₹2,500 crore for new acquisitions and greenfield projects. KIMS aims to increase its revenue from ₹1,573 crore to ₹5,727 crore and add 3,000 beds over five years.
Read the summary - Medium impact
KIMS seeks shareholder approval for QIP of ₹1500 crore
KIMS is seeking shareholder approval for a Qualified Institutions Placement (QIP) to raise up to ₹1500 crore by issuing equity shares. The e-voting period runs from March 17, 2026, to April 15, 2026. Results will be announced by March 17, 2026.
Read the summary - Low impact
KIMS to hold Investor Meet on March 23, 2026 with DAM Capital
Krishna Institute of Medical Sciences Limited (KIMS) will conduct an Analyst/Institutional Investor Meeting on March 23, 2026. The meeting, a Group Meeting with DAM Capital, will be held in Mumbai, India, and will focus on the Hospitals & Diagnostics sector. No Unpublished Price Sensitive Information will be disclosed.
Read the summary - Low impact
KIMS Schedules Analyst/Institutional Investor Meeting for March 18, 2026
Krishna Institute of Medical Sciences Limited (KIMS) will hold an Analyst/Institutional Investor Meeting on March 18, 2026, via Zoom. No Unpublished Price Sensitive Information will be shared. The schedule is subject to change.
Read the summary - High impact
KIMS Board Approves Fund Raising Up To ₹1,500 Crore Via QIP
Krishna Institute of Medical Sciences Limited's Board approved raising up to ₹1,500 Crores via Qualified Institutions Placements (QIP). The Finance & Investment Committee is authorized to finalize terms. A postal ballot notice will be issued to seek member approval for the fundraise.
Read the summary - Low impact
KIMS to participate in Kotak Securities 'Chasing Growth 2026' investors conference on Feb 25, 2026
Krishna Institute of Medical Sciences Limited (KIMS) will attend the 'Chasing Growth 2026' investors conference hosted by Kotak Securities in Mumbai on February 25, 2026. This is a group meeting with investors, and no price-sensitive information will be disclosed.
Read the summary - Low impact
KIMS Schedules Analyst/Institutional Investor Meeting on Feb 19, 2026
Krishna Institute of Medical Sciences Limited (KIMS) will hold a virtual Analyst/Institutional Investor Meeting on February 19, 2026, with Lion Global Investors. No Unpublished Price Sensitive Information will be disclosed.
Read the summary - Medium impact
KIMS Hospitals Q3 FY26 Earnings Call Transcript Released
KIMS Hospitals released its Q3 FY26 earnings call transcript. The company reported record revenue of ₹1,003 crores, up 2.2% YoY, but EBITDA declined 0.4% YoY to ₹204 crores. New units are stabilizing, with expected real growth from FY27. A new hospital agreement in Chennai was also signed.
Read the summary - Low impact
KIMS: Audio Recording of Q3 FY26 Investor Conference Call Available Online
Krishna Institute of Medical Sciences Limited (KIMS) has released the audio recording of its Q3 FY26 investor and analyst conference call, held on February 9, 2026. The recording is accessible on the company's website under investor disclosures.
Read the summary - Low impact
KIMS Corrects Board Meeting Outcome: Auditor Name and Shareholding Updated
KIMS corrected its Board Meeting outcome from February 6th, 2026. The statutory auditor's name was updated to S.R. Batliboi & Associates LLP. The company's shareholding was corrected to 75.83% from 75.53%. Other details remain unchanged.
Read the summary - Medium impact
KIMS Hospitals Announces Newspaper Publication of Q3 FY26 Financial Results
KIMS published its Q3 FY26 results on Feb 6, 2026. The company announced strategic expansion plans, including a new multi-specialty hospital and the acquisition of a hospital in Karimnagar for ₹2.89 crore. Bed capacity is expected to reach 14,322 by end FY26 and 18,330 by end FY27.
Read the summary - Medium impact
KIMS Hospitals Q3 FY26: Revenue Up 29.2% to ₹997.7 Crore, EBITDA Margins at 20.4%
Krishna Institute of Medical Sciences Limited (KIMS) reported Q3 FY26 operating revenue of ₹997.7 crore, up 29.2% YoY. Nine-month revenue increased 25.6% to ₹2,846.5 crore. Q3 EBITDA was ₹204.1 crore (down 0.4% YoY) with margins at 20.4%. Operational metrics showed growth, with IP volume up 13.2% and OP volume up 24.5%.
Read the summary - Medium impact
KIMS to Invest Up To ₹100 Crore More in Sarvejana Healthcare for Increased Stake
KIMS announced an additional investment of up to ₹100 Crores in its material subsidiary, Sarvejana Healthcare Private Limited (Sunshine Hospital). KIMS currently holds a 75.53% stake and aims to increase this by acquiring shares from minority shareholders. Sunshine Hospital reported a turnover of ₹597 Crores for FY25.
Read the summary - Medium impact
KIMS to increase investment in Sarvejana Healthcare by ₹100 Cr; Approves Q3 FY26 Results
KIMS approved Q3 FY26 results and decided to increase its investment limit by up to ₹100 Crores in its material subsidiary, Sarvejana Healthcare Private Limited (Sunshine Hospital). KIMS currently holds a 75.53% stake in Sunshine Hospital, which reported a turnover of ₹597 Crores for FY25.
Read the summary - Medium impact
KIMS Board Approves Q3 FY26 Results, Increases Subsidiary Acquisition Limit by ₹100 Cr
KIMS board approved Q3 FY26 unaudited standalone and consolidated financial results. The company also approved increasing the acquisition limit for its material subsidiary, Sarvejana Healthcare Private Limited, by ₹100 Crores. Sunshine Hospital, the subsidiary, had a turnover of ₹597 Crores in FY25.
Read the summary - Low impact
KIMS to attend Axis Capital Flagship India Conference on Feb 10, 2026
Krishna Institute of Medical Sciences Limited will attend the Axis Capital Flagship India Conference in Mumbai on February 10, 2026. This investor meet is a group meeting.
Read the summary - Low impact
KIMS Hospitals Revises Investor Call Date to Feb 9, 2026, Post Q3 FY26 Results
Krishna Institute of Medical Sciences Limited (KIMS) will host a revised investor conference call on February 9, 2026, at 9:30 a.m. IST. The call, organized by IIFL Capital, follows the declaration of the company's Q3 FY26 financial results. Management will discuss business strategy and outlook.
Read the summary - Medium impact
KIMS Shareholders Approve Material Related Party Transaction with Subsidiary
KIMS shareholders approved a material related party transaction with subsidiary KIMS Hospital Bengaluru. The ordinary resolution passed with overwhelming support, including 100% from promoters and strong backing from institutional and non-institutional public shareholders. The postal ballot concluded on February 1, 2026.
Read the summary - Low impact
KIMS to Host Analyst Call on Feb 7th Post Q3FY26 Results to Discuss Strategy
KIMS management will participate in a conference call hosted by IIFL Capital on February 7, 2026, at 10:30 am IST. The call will focus on the company's business strategy and outlook following the Q3FY26 financial results announcement. Key management personnel including the MD, CEO, and CFO will be present.
Read the summary - Low impact
KIMS Files SEBI Certificate for Q3 FY26 Dematerialization
Krishna Institute of Medical Sciences Limited (KIMS) has submitted a SEBI compliance certificate for the quarter ended December 31, 2025. The certificate, received from its registrar MUFG Intime India Private Limited, confirms the processing of dematerialized securities.
Read the summary - Low impact
KIMS Hospitals Announces Newspaper Publication for Postal Ballot Notice
KIMS Hospitals published a newspaper notice on January 3, 2026, regarding a postal ballot for e-voting. The e-voting period is from January 1 to January 30, 2026. Results will be announced by February 2, 2026. This complies with SEBI regulations.
Read the summary - Medium impact
KIMS seeks member approval for ₹150 Crore loan to subsidiary KIMS Hospital Bengaluru
KIMS is seeking shareholder approval via postal ballot for a material related party transaction. The company plans to provide loans up to ₹150 Crore to its subsidiary, KIMS Hospital Bengaluru Private Limited (KHBPL), to fund its operations and expansion. E-voting will be open from January 3, 2026, to February 1, 2026.
Read the summary - Medium impact
KIMS Subsidiary Receives ₹12.42 Crore GST Demand Order
KIMS subsidiary, Spanv Medisearch Lifesciences Private Limited, received a GST demand order for ₹12.42 crore. The order, dated December 31, 2025, is for FY 2021-22 and requires payment by March 30, 2026. KIMS is consulting legal advisors to explore appeal options.
Read the summary - Low impact
KIMS to Close Trading Window for Q3 FY26 Results from Jan 1, 2026
Krishna Institute of Medical Sciences Limited (KIMS) will close its trading window from January 1, 2026, for its Q3 FY26 results. The window will reopen 48 hours after the financial results are announced. Directors and designated employees are restricted from trading securities during this period.
Read the summary - Medium impact
KIMS to Set Up 300-Bed Super Speciality Hospital in Chennai for ₹300 Crore
Krishna Institute of Medical Sciences Limited (KIMS) will establish a new 300-bed Super Speciality Hospital in Chennai, Tamil Nadu. The project involves leasing 1.168 acres of land and an investment of approximately ₹300 Crore. The expansion is expected to be completed within 36 months and will be financed through bank loans and internal accruals.
Read the summary - Medium impact
KIMS Increases Stake in Sarvejana Healthcare to 75.53% for ₹148.09 Crore
Krishna Institute of Medical Sciences Limited (KIMS) acquired an additional 6.94% stake in its material subsidiary, Sarvejana Healthcare Private Limited (Sunshine Hospital), for ₹148.09 crore. This increases KIMS's total holding to 75.53%. Sunshine Hospital reported a turnover of ₹597.00 crore for FY25. The acquisition was completed on December 19, 2025.
Read the summary - Medium impact
KIMS Hospitals Commences Operations at New Bengaluru Facility
KIMS Hospitals has commenced operations at its new 350-bedded, multi-specialty tertiary care hospital in Electronic City, Bengaluru, effective December 15, 2025. The facility offers advanced cardiac, neuro, oncology, organ transplant, and robotic sciences, enhancing the company's healthcare service delivery in Karnataka.
Read the summary - Low impact
KIMS to meet with 360One Capital (B&K Securities) on Dec 17, 2025
Krishna Institute of Medical Sciences Limited will hold a group meeting with 360One Capital (B&K Securities) on December 17, 2025, in Hyderabad. No Unpublished Price Sensitive Information will be shared during the meeting.
Read the summary - Low impact
KIMS to attend JM Financial India Conference on 21 Nov 2025
KIMS is scheduled to participate in the JM Financial India Conference in Mumbai on November 21, 2025, for a group meeting with analysts and institutional investors.
Read the summary - Low impact
KIMS Hospitals Announces Q2 FY26 Earnings Conference Call Transcript
KIMS Hospitals announces the transcript of the earnings conference call held on 10th November 2025 is now available on the company website.
Read the summary - Low impact
KIMS announces Analyst/Institutional Investor Meeting on November 17, 2025
KIMS announced a group meeting with analysts and institutional investors at the Avendus Spark INDX Annual Investor Conference on November 17, 2025, in Mumbai.
Read the summary - Medium impact
KIMS corrects investor presentation for Q2 FY26, clarifies no financial impact, reports mixed results
KIMS corrected its Q2 FY26 investor presentation for a bed count error, confirming no financial impact. The company reported ₹964.9 crore revenue (up 23.3% YoY) but ₹208.2 crore EBITDA (down 6.7% YoY) and ₹72 crore PAT (down 40.3% YoY).
Read the summary - Low impact
KIMS releases audio recording of Q2 FY26 analyst/investor conference call
KIMS announces the availability of the audio recording for its Q2 FY26 conference call with investors and analysts, held on November 10, 2025, on its website.
Read the summary - Low impact
KIMS announces newspaper publication of unaudited Q2 & half-year financial results for Sep 2025
KIMS announced the newspaper publication of its unaudited standalone and consolidated financial results for Q2 and half-year ended September 30, 2025, in compliance with SEBI regulations.
Read the summary - Medium impact
KIMS Hospitals Announces Investor Presentation for Q2 & Half-Year Ended Sep 30, 2025
KIMS Hospitals announced its investor presentation for Q2 & Half-Year Ended September 30, 2025. Consolidated Q2 FY26 total revenue was ₹96.49 crore, a growth of 23.3% YoY. PAT stood at ₹7.20 crore.
Read the summary - Medium impact
KIMS Hospitals Announces Q2 FY26 Results
KIMS Hospitals announced Q2 FY26 results with revenue of ₹965Cr, up 23.3% YoY. EBITDA at ₹208Cr, down 6.7% YoY. PAT at ₹72Cr. CMD optimistic about achieving FY26 targets.
Read the summary - Medium impact
KIMS Limited Announces Unaudited Standalone and Consolidated Financial Results for Quarter Ended September 30, 2025
KIMS Limited declared unaudited financial results for quarter ended Sept 30, 2025. Both standalone and consolidated results were reviewed by auditors and approved by the Board.
Read the summary - Medium impact
KIMS Board Approves Merger of Wholly-Owned Subsidiaries KIMS Hospitals and Chalasani Hospitals
KIMS Board approved the merger of its wholly-owned subsidiaries, KIMS Hospitals and Chalasani Hospitals, to simplify structure, improve efficiency, and consolidate financials.
Read the summary - Medium impact
KIMS approves Q2FY26 Results, Merger of wholly-owned subsidiaries
KIMS approves Q2FY26 results and merger of subsidiaries at board meeting on November 7, 2025.
Read the summary - High impact
KIMS Board Approves Q2 Results and Merger of Wholly-Owned Subsidiaries
KIMS Board approved Q2 and half-year financial results ended September 30, 2025, showing growth. The Board also approved the merger of two wholly-owned subsidiaries with the company, consolidating operations.
Read the summary - Medium impact
KIMS to host conference call on Nov 10, 2025, to discuss Q2FY26 results and business strategy
KIMS is holding an analyst/investor conference call on November 10, 2025, at 9:00 am IST, to discuss Q2FY26 results and future business strategy and outlook.
Read the summary - Medium impact
KIMS's shareholding in Arunodaya Hospitals diluted to 64.36% post preferential allotment
KIMS's equity shareholding in subsidiary Arunodaya Hospitals diluted from 70.67% to 64.36% following a preferential allotment. Arunodaya remains a KIMS subsidiary.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio - Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio - Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio - Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio